About the Authors
- Yu K. Tong
-
Affiliations Centre for Research into Circulating Fetal Nucleic Acids, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, China, Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, China
- Rossa W. K. Chiu
-
Affiliations Centre for Research into Circulating Fetal Nucleic Acids, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, China, Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, China
- Ranjit Akolekar
-
Affiliation Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, London, United Kingdom
- Tak Y. Leung
-
Affiliation Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, China
- Tze K. Lau
-
Affiliation Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, China
- Kypros H. Nicolaides
-
Affiliation Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, London, United Kingdom
- Y. M. Dennis Lo
-
* E-mail: loym@cuhk.edu.hk
Affiliations Centre for Research into Circulating Fetal Nucleic Acids, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, China, Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, China
Competing Interests
YKT, RWKC and YMDL hold patents and have filed patent applications on aspects of the use of fetal nucleic acids in maternal plasma for noninvasive prenatal diagnosis, a proportion of which has been licensed to Sequenom, Inc. YMDL holds equities in and is a consultant for Sequenom Inc. The authors confirm that their patent position does not alter their adherence to all of the PLoS ONE policies.
Author Contributions
Conceived and designed the experiments: RWKC YMDL. Performed the experiments: YKT. Analyzed the data: YKT RWKC YMDL. Contributed reagents/materials/analysis tools: RA TYL TKL KHN. Wrote the paper: YKT RWKC YMDL.